The size of the Asia Pacific Alzheimer’s disease Therapeutics and Diagnostics Market was worth USD 2663.21 Million in 2021 and is estimated to be growing at a CAGR of 5.39%, to reach USD 3462.59 Million by 2026.
The aging population is a primary driver of the market for Alzheimer's therapeutics and diagnostics in the APAC region. Rising life expectancy is contributing to rapid rises in the number of older people and an increase in the prevalence of chronic diseases such as dementia. Treatments for Alzheimer's disease provide only transient and unreliable benefits in people's well-being, and none of the approved medications can alter the illness's progression. As a result of the size of the affected population and the lack of appropriate and effective treatment, pharmacy producers have a huge opportunity. Increased pipeline drug research, investment in biomarkers for drug development, and better diagnostics for early detection are all propelling this market forward. However, drug producers have been unable to demonstrate significant therapeutic benefits of treatment for several novel substances due to rigorous rules. Collaboration between current players is one of the most notable trends. Specifically, diagnostic technology companies are working diligently to develop effective biomarker technologies to support and improve the drug development for new medication candidates, which are projected to drive demand even higher.
The expansion of the APAC Alzheimer’s disease therapeutics and diagnostics market is expected to be hampered by strict requirements for medication development and clinical trials. The high expense of medications used to treat Alzheimer's disease also plays a role. Furthermore, the shortage of qualified medical practitioners in underdeveloped countries impedes the growth of the Alzheimer's disease treatments and diagnostics market. In addition, the Alzheimer's disease therapeutics and diagnostics market has had a substantial growth hurdle throughout the projection period due to a lack of understanding about novel treatments used to treat the condition.
This research report on the Asia Pacific Alzheimer’s disease Therapeutics and Diagnostics Market has been segmented & sub-segmented into the following categories:
By Therapeutics:
By Diagnostics:
By Country:
Geographically, Asia-Pacific is the fastest-growing market for Alzheimer's disease medicines and diagnostics. The key driver of the Alzheimer's disease pharmaceuticals and diagnostics market in China is the Alzheimer's rapidly growing population, which is resulting in a growing elderly population. As a result of the aging population's vulnerability to diseases like dementia, dementia is becoming more prevalent, particularly in semi-urban and rural areas. According to the Ministry of Health, China is one of the leading countries in terms of the number of people affected by dementia, accounting for almost 20% of all dementia cases worldwide. This market is predicted to grow at the fastest rate during the forecast period, owing to an increase in the aging population in Asia Pacific's growing regions. For this market, developing countries are likely to provide attractive potential. According to Alzheimer's disease International, 59 percent of dementia patients live in developing nations in 2015; however, this number is expected to climb to 69 percent by 2050. China, India, and their south Asian and western Pacific neighbors have the fastest-growing elderly populations.
KEY MARKET PLAYERS:
Companies playing a notable role in the APAC Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals, etc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutics
5.1.1 Introduction
5.1.2 Marketed Drugs
5.1.2.1 NMDA Receptor Antagonists
5.1.2.2 Cholinesterase Inhibitors
5.1.3 Pipeline Drugs
5.1.4 Y-o-Y Growth Analysis, By Therapeutics
5.1.5 Market Attractiveness Analysis, By Therapeutics
5.1.6 Market Share Analysis, By Therapeutics
5.2 Diagnostics
5.2.1 Introduction
5.2.2 Computed tomography scan
5.2.3 Electroencephalography
5.2.4 Lumbar puncture test
5.2.5 Magnetic resonance imaging
5.2.6 Positron emission tomography
5.2.7 Others
5.2.8 Y-o-Y Growth Analysis, By Diagnostics
5.2.9 Market Attractiveness Analysis, By Diagnostics
5.2.10 Market Share Analysis, By Diagnostics
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutics
6.1.3.3 By Diagnostics
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutics
6.1.4.3 By Diagnostics
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapeutics
6.1.5.3 By Diagnostics
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbvie Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 AC Immune SA
8.4 Eisai Co Ltd.
8.5 Allergan PLC
8.6 Novartis AG
8.7 Amarantus Bioscience Holdings
8.8 H. Lundbeck A/S
8.9 Anavex LifeSciencescs
8.10 Avid Radiopharmaceuticals
8.11 Forest Laboratories Inc.
8.12 Axon Neuroscience
8.13 Daiichi Sankyo Co
8.14 TauRx Therapeutics Ltd
8.15 Eli Lilly
8.16 F. Hoffmann La Roche AG
8.17 Johnson & Johnson
8.18 GE Healthcare
8.19 Janssen Pharmaceuticals
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
